Michelle Barron
Concepts (285)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza Vaccines | 10 | 2026 | 541 | 1.410 |
Why?
| | Influenza, Human | 9 | 2026 | 634 | 1.040 |
Why?
| | Hospitalization | 23 | 2026 | 2468 | 0.860 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1030 | 0.670 |
Why?
| | Ambulatory Care | 7 | 2025 | 627 | 0.650 |
Why?
| | Mycobacterium tuberculosis | 1 | 2024 | 325 | 0.640 |
Why?
| | Influenza A Virus, H1N1 Subtype | 3 | 2025 | 161 | 0.580 |
Why?
| | Hemorrhagic Fever, Ebola | 2 | 2015 | 82 | 0.520 |
Why?
| | Emergency Service, Hospital | 14 | 2025 | 2357 | 0.510 |
Why?
| | Vaccines, Inactivated | 1 | 2016 | 70 | 0.470 |
Why?
| | Vaccines, Attenuated | 1 | 2016 | 129 | 0.460 |
Why?
| | Pregnancy Complications, Infectious | 3 | 2025 | 437 | 0.460 |
Why?
| | Viremia | 2 | 2009 | 158 | 0.450 |
Why?
| | Adult | 44 | 2026 | 40821 | 0.430 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 39 | 0.430 |
Why?
| | Staphylococcal Infections | 6 | 2020 | 396 | 0.390 |
Why?
| | Vaccination | 10 | 2026 | 1444 | 0.380 |
Why?
| | Middle Aged | 37 | 2026 | 36359 | 0.380 |
Why?
| | Antifungal Agents | 9 | 2020 | 153 | 0.380 |
Why?
| | Antibodies, Viral | 1 | 2016 | 683 | 0.360 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2009 | 700 | 0.340 |
Why?
| | Aged | 29 | 2026 | 26251 | 0.330 |
Why?
| | Dendritic Cells | 2 | 2006 | 507 | 0.330 |
Why?
| | Case-Control Studies | 12 | 2026 | 3633 | 0.320 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 458 | 0.310 |
Why?
| | Serotonin Syndrome | 1 | 2010 | 4 | 0.310 |
Why?
| | Humans | 65 | 2026 | 145625 | 0.310 |
Why?
| | Oxazolidinones | 1 | 2010 | 16 | 0.310 |
Why?
| | Bacteremia | 3 | 2020 | 218 | 0.300 |
Why?
| | Immunization, Secondary | 4 | 2022 | 93 | 0.300 |
Why?
| | Acetamides | 1 | 2010 | 42 | 0.300 |
Why?
| | United States | 21 | 2026 | 16041 | 0.290 |
Why?
| | Influenza A Virus, H3N2 Subtype | 2 | 2026 | 50 | 0.290 |
Why?
| | Methicillin | 1 | 2009 | 10 | 0.290 |
Why?
| | Adaptive Immunity | 1 | 2009 | 172 | 0.270 |
Why?
| | HIV-1 | 2 | 2006 | 911 | 0.270 |
Why?
| | Female | 39 | 2026 | 79080 | 0.270 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 4 | 2020 | 253 | 0.270 |
Why?
| | Platelet Transfusion | 1 | 2009 | 76 | 0.270 |
Why?
| | Cytomegalovirus Infections | 1 | 2009 | 203 | 0.260 |
Why?
| | Male | 36 | 2026 | 73014 | 0.260 |
Why?
| | Adolescent | 21 | 2026 | 22451 | 0.250 |
Why?
| | Immunocompromised Host | 4 | 2024 | 201 | 0.250 |
Why?
| | Anti-Infective Agents | 1 | 2010 | 234 | 0.250 |
Why?
| | Vitamin K Deficiency | 1 | 2006 | 9 | 0.230 |
Why?
| | AIDS Vaccines | 1 | 2006 | 53 | 0.230 |
Why?
| | Rhizopus | 1 | 2005 | 3 | 0.220 |
Why?
| | Facial Pain | 1 | 2005 | 12 | 0.220 |
Why?
| | Blood Platelets | 1 | 2009 | 380 | 0.220 |
Why?
| | Mucormycosis | 1 | 2005 | 18 | 0.220 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 138 | 0.210 |
Why?
| | Cross Infection | 3 | 2014 | 258 | 0.210 |
Why?
| | Young Adult | 16 | 2026 | 14240 | 0.210 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 298 | 0.210 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2024 | 39 | 0.200 |
Why?
| | Klebsiella Infections | 2 | 2014 | 26 | 0.200 |
Why?
| | Carbapenems | 2 | 2014 | 28 | 0.200 |
Why?
| | Chaetomium | 1 | 2003 | 3 | 0.200 |
Why?
| | Klebsiella pneumoniae | 2 | 2014 | 48 | 0.200 |
Why?
| | beta-Lactamases | 2 | 2014 | 54 | 0.200 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 415 | 0.200 |
Why?
| | Immunity, Innate | 1 | 2009 | 843 | 0.200 |
Why?
| | Aged, 80 and over | 11 | 2026 | 8351 | 0.200 |
Why?
| | Petroleum | 1 | 2023 | 10 | 0.190 |
Why?
| | Petroleum Pollution | 1 | 2023 | 11 | 0.190 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2024 | 127 | 0.190 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2024 | 139 | 0.190 |
Why?
| | Mycoses | 1 | 2003 | 86 | 0.190 |
Why?
| | Candidiasis, Invasive | 2 | 2014 | 6 | 0.190 |
Why?
| | Sinusitis | 1 | 2005 | 220 | 0.180 |
Why?
| | Sputum | 1 | 2024 | 302 | 0.180 |
Why?
| | Brain Diseases | 1 | 2003 | 157 | 0.180 |
Why?
| | Viral Vaccines | 1 | 2023 | 107 | 0.180 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 584 | 0.170 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2002 | 237 | 0.170 |
Why?
| | Tuberculosis | 1 | 2024 | 289 | 0.160 |
Why?
| | Pericarditis | 1 | 2020 | 11 | 0.160 |
Why?
| | Cryptococcus neoformans | 1 | 2020 | 21 | 0.160 |
Why?
| | Cryptococcosis | 1 | 2020 | 31 | 0.150 |
Why?
| | Lung Transplantation | 2 | 2013 | 326 | 0.150 |
Why?
| | Water Pollutants, Chemical | 1 | 2023 | 227 | 0.150 |
Why?
| | Zygomycosis | 2 | 2009 | 6 | 0.150 |
Why?
| | Organ Transplantation | 3 | 2020 | 235 | 0.150 |
Why?
| | Seasons | 3 | 2026 | 535 | 0.140 |
Why?
| | Nafcillin | 1 | 2018 | 3 | 0.140 |
Why?
| | Intensive Care Units | 5 | 2021 | 923 | 0.140 |
Why?
| | Cefazolin | 1 | 2018 | 22 | 0.140 |
Why?
| | Retrospective Studies | 9 | 2024 | 17291 | 0.130 |
Why?
| | RNA, Messenger | 5 | 2024 | 2783 | 0.130 |
Why?
| | Pneumonia | 1 | 2024 | 633 | 0.130 |
Why?
| | Child, Preschool | 8 | 2026 | 11888 | 0.130 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2016 | 38 | 0.120 |
Why?
| | Disease Outbreaks | 3 | 2015 | 420 | 0.120 |
Why?
| | Echinocandins | 2 | 2014 | 8 | 0.120 |
Why?
| | Influenza B virus | 2 | 2026 | 47 | 0.120 |
Why?
| | North America | 1 | 2016 | 299 | 0.110 |
Why?
| | Spores, Bacterial | 1 | 2015 | 18 | 0.110 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 29 | 0.110 |
Why?
| | Containment of Biohazards | 1 | 2015 | 23 | 0.110 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2015 | 20 | 0.110 |
Why?
| | Mental Disorders | 1 | 2024 | 1133 | 0.110 |
Why?
| | Anti-Bacterial Agents | 4 | 2020 | 1935 | 0.110 |
Why?
| | Population Surveillance | 2 | 2015 | 477 | 0.110 |
Why?
| | Child | 9 | 2026 | 22638 | 0.110 |
Why?
| | Infant | 6 | 2026 | 10093 | 0.110 |
Why?
| | Coinfection | 1 | 2016 | 143 | 0.100 |
Why?
| | Microbial Sensitivity Tests | 3 | 2020 | 367 | 0.100 |
Why?
| | Renal Replacement Therapy | 1 | 2015 | 102 | 0.100 |
Why?
| | Bacterial Infections | 1 | 2016 | 246 | 0.100 |
Why?
| | Pulmonary Aspergillosis | 1 | 2013 | 4 | 0.100 |
Why?
| | Treatment Outcome | 9 | 2020 | 11744 | 0.100 |
Why?
| | Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 19 | 0.100 |
Why?
| | Heart Transplantation | 1 | 2020 | 679 | 0.100 |
Why?
| | Virus Diseases | 1 | 2016 | 219 | 0.100 |
Why?
| | Antibodies, Neutralizing | 1 | 2016 | 346 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2015 | 247 | 0.100 |
Why?
| | Vaccines, Combined | 2 | 2023 | 49 | 0.100 |
Why?
| | Invasive Pulmonary Aspergillosis | 1 | 2013 | 7 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 31 | 0.090 |
Why?
| | Daptomycin | 1 | 2013 | 18 | 0.090 |
Why?
| | Creatine Kinase | 1 | 2013 | 70 | 0.090 |
Why?
| | Rectum | 1 | 2014 | 180 | 0.090 |
Why?
| | Drug Interactions | 2 | 2013 | 403 | 0.090 |
Why?
| | Risk Factors | 8 | 2024 | 10840 | 0.090 |
Why?
| | Muscular Diseases | 1 | 2013 | 110 | 0.090 |
Why?
| | Critical Care | 2 | 2016 | 700 | 0.090 |
Why?
| | Antiviral Agents | 3 | 2026 | 774 | 0.090 |
Why?
| | Global Health | 1 | 2015 | 402 | 0.090 |
Why?
| | Laboratories | 2 | 2021 | 109 | 0.080 |
Why?
| | Chemoprevention | 1 | 2011 | 91 | 0.080 |
Why?
| | Sertraline | 1 | 2010 | 26 | 0.080 |
Why?
| | Graft Rejection | 1 | 2013 | 504 | 0.080 |
Why?
| | Linezolid | 1 | 2010 | 25 | 0.080 |
Why?
| | Citalopram | 1 | 2010 | 33 | 0.080 |
Why?
| | Lung Diseases, Fungal | 1 | 2009 | 12 | 0.070 |
Why?
| | Tremor | 1 | 2010 | 98 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 448 | 0.070 |
Why?
| | Hospital Mortality | 2 | 2023 | 1037 | 0.070 |
Why?
| | Pregnancy | 3 | 2025 | 7217 | 0.060 |
Why?
| | Sequence Analysis, DNA | 2 | 2024 | 771 | 0.060 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 861 | 0.060 |
Why?
| | Newspapers as Topic | 1 | 2006 | 7 | 0.060 |
Why?
| | Professional Misconduct | 1 | 2006 | 13 | 0.060 |
Why?
| | Ethics, Research | 1 | 2006 | 32 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2006 | 49 | 0.060 |
Why?
| | Hemorrhagic Disorders | 1 | 2006 | 10 | 0.060 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2006 | 26 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2009 | 481 | 0.060 |
Why?
| | Gene Products, gag | 1 | 2006 | 38 | 0.060 |
Why?
| | Drug Antagonism | 1 | 2006 | 10 | 0.060 |
Why?
| | Prothrombin Time | 1 | 2006 | 32 | 0.060 |
Why?
| | Phenytoin | 1 | 2006 | 21 | 0.060 |
Why?
| | T-Lymphocytes | 2 | 2006 | 2007 | 0.060 |
Why?
| | Vitamin K | 1 | 2006 | 46 | 0.060 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2006 | 128 | 0.060 |
Why?
| | Amphotericin B | 1 | 2005 | 36 | 0.050 |
Why?
| | Recombination, Genetic | 1 | 2006 | 202 | 0.050 |
Why?
| | Thrombolytic Therapy | 1 | 2006 | 165 | 0.050 |
Why?
| | Immunity, Herd | 1 | 2024 | 7 | 0.050 |
Why?
| | Tissue Plasminogen Activator | 1 | 2006 | 244 | 0.050 |
Why?
| | Pain | 1 | 2010 | 787 | 0.050 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2024 | 81 | 0.050 |
Why?
| | Autopsy | 1 | 2003 | 96 | 0.050 |
Why?
| | Spermine | 1 | 2023 | 29 | 0.050 |
Why?
| | Oils | 1 | 2023 | 22 | 0.050 |
Why?
| | Hydrocarbons | 1 | 2023 | 29 | 0.050 |
Why?
| | Fibrinolytic Agents | 1 | 2006 | 302 | 0.050 |
Why?
| | Anticonvulsants | 1 | 2006 | 251 | 0.050 |
Why?
| | B7-2 Antigen | 1 | 2002 | 27 | 0.050 |
Why?
| | Hodgkin Disease | 1 | 2005 | 173 | 0.050 |
Why?
| | Time Factors | 4 | 2022 | 7079 | 0.050 |
Why?
| | Fatal Outcome | 1 | 2003 | 302 | 0.050 |
Why?
| | Liposomes | 1 | 2005 | 268 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
| | Receptors, CCR5 | 1 | 2002 | 59 | 0.050 |
Why?
| | CD40 Antigens | 1 | 2002 | 67 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2002 | 90 | 0.050 |
Why?
| | Brain Ischemia | 1 | 2006 | 362 | 0.050 |
Why?
| | Advisory Committees | 1 | 2024 | 228 | 0.050 |
Why?
| | Prospective Studies | 3 | 2024 | 8087 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2006 | 1136 | 0.040 |
Why?
| | HLA-DR Antigens | 1 | 2002 | 211 | 0.040 |
Why?
| | Vaccination Coverage | 1 | 2023 | 106 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2002 | 324 | 0.040 |
Why?
| | Survival Analysis | 2 | 2016 | 1372 | 0.040 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2002 | 278 | 0.040 |
Why?
| | Lipopeptides | 2 | 2014 | 17 | 0.040 |
Why?
| | Pericardiocentesis | 1 | 2020 | 10 | 0.040 |
Why?
| | Fluconazole | 1 | 2020 | 24 | 0.040 |
Why?
| | Immunization Schedule | 1 | 2021 | 186 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 495 | 0.040 |
Why?
| | Water | 1 | 2023 | 451 | 0.040 |
Why?
| | Hospitals | 2 | 2015 | 730 | 0.040 |
Why?
| | Double-Blind Method | 2 | 2015 | 2064 | 0.040 |
Why?
| | Antigens, CD | 1 | 2002 | 559 | 0.040 |
Why?
| | Vancomycin | 1 | 2020 | 96 | 0.040 |
Why?
| | RNA, Viral | 1 | 2002 | 691 | 0.030 |
Why?
| | Vascular Grafting | 1 | 2018 | 14 | 0.030 |
Why?
| | Prevalence | 1 | 2006 | 2852 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2006 | 2497 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2006 | 4112 | 0.030 |
Why?
| | Cytokines | 1 | 2006 | 2079 | 0.030 |
Why?
| | Endocarditis | 1 | 2018 | 40 | 0.030 |
Why?
| | Incidence | 2 | 2016 | 2910 | 0.030 |
Why?
| | Echocardiography | 1 | 2020 | 645 | 0.030 |
Why?
| | Patient Readmission | 1 | 2021 | 771 | 0.030 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2015 | 26 | 0.030 |
Why?
| | Contraindications | 1 | 2015 | 88 | 0.030 |
Why?
| | Developed Countries | 1 | 2015 | 38 | 0.030 |
Why?
| | Patient Isolation | 1 | 2015 | 20 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2002 | 3005 | 0.030 |
Why?
| | Africa | 1 | 2015 | 119 | 0.030 |
Why?
| | Body Fluids | 1 | 2015 | 70 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2015 | 67 | 0.030 |
Why?
| | Water-Electrolyte Imbalance | 1 | 2015 | 38 | 0.030 |
Why?
| | Age Distribution | 1 | 2015 | 395 | 0.030 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2015 | 96 | 0.030 |
Why?
| | Ebolavirus | 1 | 2015 | 91 | 0.030 |
Why?
| | Diarrhea | 1 | 2015 | 190 | 0.030 |
Why?
| | Travel | 1 | 2015 | 133 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2016 | 6449 | 0.020 |
Why?
| | Colorado | 2 | 2014 | 4588 | 0.020 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 119 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2014 | 328 | 0.020 |
Why?
| | Rosuvastatin Calcium | 1 | 2013 | 21 | 0.020 |
Why?
| | Fluorobenzenes | 1 | 2013 | 17 | 0.020 |
Why?
| | Allografts | 1 | 2013 | 148 | 0.020 |
Why?
| | Drug Resistance, Bacterial | 1 | 2014 | 185 | 0.020 |
Why?
| | Simvastatin | 1 | 2013 | 58 | 0.020 |
Why?
| | Muscular Dystrophies | 1 | 1992 | 29 | 0.020 |
Why?
| | Dystrophin | 1 | 1992 | 40 | 0.020 |
Why?
| | Feces | 1 | 2015 | 494 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 1125 | 0.020 |
Why?
| | APACHE | 1 | 2011 | 67 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1500 | 0.020 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2014 | 272 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1531 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1652 | 0.020 |
Why?
| | Risk | 1 | 2013 | 917 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2112 | 0.020 |
Why?
| | Neoplasms | 1 | 2006 | 2944 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2015 | 711 | 0.020 |
Why?
| | Anticoagulants | 1 | 2015 | 743 | 0.020 |
Why?
| | Pyrimidines | 1 | 2013 | 530 | 0.020 |
Why?
| | Patient Care Team | 1 | 2015 | 700 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 74 | 0.020 |
Why?
| | Sulfonamides | 1 | 2013 | 592 | 0.020 |
Why?
| | Delivery of Health Care | 1 | 2015 | 942 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 319 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1581 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 179 | 0.020 |
Why?
| | Los Angeles | 1 | 2006 | 73 | 0.020 |
Why?
| | Postoperative Complications | 2 | 2009 | 2962 | 0.020 |
Why?
| | Brain Damage, Chronic | 1 | 2006 | 17 | 0.020 |
Why?
| | Echo-Planar Imaging | 1 | 2006 | 24 | 0.010 |
Why?
| | Mass Screening | 1 | 2015 | 1300 | 0.010 |
Why?
| | Ethics Committees, Research | 1 | 2006 | 41 | 0.010 |
Why?
| | Enzyme Induction | 1 | 2006 | 87 | 0.010 |
Why?
| | Convalescence | 1 | 2006 | 19 | 0.010 |
Why?
| | Drug Approval | 1 | 2006 | 93 | 0.010 |
Why?
| | Leukocyte Count | 1 | 2006 | 319 | 0.010 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1062 | 0.010 |
Why?
| | Peptides, Cyclic | 1 | 2006 | 276 | 0.010 |
Why?
| | Multicenter Studies as Topic | 1 | 2006 | 413 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 824 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 845 | 0.010 |
Why?
| | Risk Assessment | 1 | 2013 | 3678 | 0.010 |
Why?
| | Research | 1 | 2006 | 421 | 0.010 |
Why?
| | Patient Selection | 1 | 2006 | 720 | 0.010 |
Why?
| | Lung | 1 | 2013 | 4119 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 6045 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2006 | 2910 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2006 | 5397 | 0.010 |
Why?
| | Biomarkers | 1 | 2006 | 4329 | 0.010 |
Why?
| | Brain | 1 | 2006 | 2981 | 0.010 |
Why?
| | DNA Probes | 1 | 1992 | 57 | 0.010 |
Why?
| | X Chromosome | 1 | 1992 | 66 | 0.010 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1992 | 43 | 0.010 |
Why?
| | Chromosome Deletion | 1 | 1992 | 126 | 0.010 |
Why?
| | Sex Chromosome Aberrations | 1 | 1992 | 67 | 0.010 |
Why?
| | Muscles | 1 | 1992 | 330 | 0.010 |
Why?
| | Exons | 1 | 1992 | 361 | 0.010 |
Why?
| | Blotting, Western | 1 | 1992 | 1176 | 0.000 |
Why?
| | Biopsy | 1 | 1992 | 1073 | 0.000 |
Why?
| | Antibodies, Monoclonal | 1 | 1992 | 1511 | 0.000 |
Why?
|
|
Barron's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|